<DOC>
	<DOC>NCT03037489</DOC>
	<brief_summary>This is a multicentre, open-label, one-arm Phase II extension study to evaluate the safety and tolerability of MIV-711 in patients with knee joint osteoarthritis (OA).</brief_summary>
	<brief_title>A Study to Evaluate Safety and Tolerability of MIV-711 in Osteoarthritis Patients</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis, Knee</mesh_term>
	<criteria>Previously enrolled in the MIV711201 study including completion of Visit 8 either by Receiving MIV711 200 mg and had nonsignificant clinical worsening on the primary endpoint as defined by NRS increase of ≤2 OR by Receiving placebo and had a clinically significant worsening on the primary endpoint as defined by NRS increase of ≥2 The presence of any inflammatory arthritis Any generalized pain condition that may interfere with the evaluation of the target knee pain (e.g., fibromyalgia) as judged by the investigator. Any clinically severe or significant uncontrolled concurrent illness, which, in the opinion of the Investigator, would impair ability to give informed consent or take part in or complete this clinical study. Known or suspected intolerance or hypersensitivity to the investigational product, closely related compounds, or any of the stated ingredients.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>81 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>